This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Topic: clinical trials

February 15, 2018
Each year, around 25,000 people take part in a clinical trial that is supported by Cancer Research UK

Cancer Research UK has announced that £45million will be invested into its network of clinical trials units across the UK, one of the charity's largest investments in clinical research to date.

Cancer Research UK’s clinical trials units (CTUs) bring together world leading researchers and clinicians to find life-saving new treatments and tests for cancer patients.

September 22, 2017
Haselmeier’s injection pens provide the flexibility and efficiency required to run an effective clinical trial

Whoever is the first to bring a new therapy to the market determines the price. Therefore, every company will make the best effort to ensure a quick start to, and smooth conduct of, clinical trials.

If the drug has to be injected subcutaneously, injection pens offer a great opportunity to control the time factor. Generally, during the clinical phase, medication is stored in vials and administered to the patient through a disposable syringe.

September 19, 2016
Real world findings demonstrate that Tecfidera reduced the risk of first relapse versus competitors

Data presented, from both real-world and clinical settings, demonstrate that dimethyl fumarate delivers consistent1and sustained efficacy2 among patients with relapsing-remitting multiple sclerosis (RRMS),and adds to its well-characterised safety profile for up to nine years of treatment.3

August 10, 2015
Cancer Research UK’s Drug Discovery Committee* has awarded Newcastle University’s Northern Institute of Cancer Research £5M to bring more cancer drugs to clinical trials

The award will be given over five years and is designed to help build on Newcastle’s success in drug development. The extra money will help fund a programme of six to eight research projects, which will examine new strategies to develop medicines for cancer treatment.

June 18, 2015
Swedish Orphan Biovitrum AB (publ) (Sobi) and collaboration partner Biogen will present 23 company-sponsored platform and poster presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2015 congress taking place in Toronto, Canada, 20–25 June 2015. The data presented underscore the companies' ongoing commitment to haemophilia through continued research within the joint development programmes in haemophilia.

Swedish Orphan Biovitrum AB (publ) (Sobi) and collaboration partner Biogen will present 23 company-sponsored platform and poster presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2015 congress taking place in Toronto, Canada, 20–25 June 2015. The data presented underscore the companies' ongoing commitment to haemophilia through continued research within the joint development programmes in haemophilia.

June 16, 2015
New analyses from the EINSTEIN Clinical Trial Programme provide further data regarding the positive benefit-risk profile of Xarelto in specific patient populations. (1) Observational data from independent study in the UK provide real life insights into the risk of VTE in patients with active cancer. (1)

New analyses from the EINSTEIN Clinical Trial Programme provide further data regarding the positive benefit-risk profile of Xarelto in specific patient populations. (1) Observational data from independent study in the UK provide real life insights into the risk of VTE in patients with active cancer. (1)

March 10, 2015
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced that the first patient has been enrolled in the Phase IIa “SAPHIR” clinical study of its lead product PQ912 at the Alzheimer Centre, VU Medical Centre (VUmc), Amsterdam.

Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced that the first patient has been enrolled in the Phase IIa “SAPHIR” clinical study of its lead product PQ912 at the Alzheimer Centre, VU Medical Centre (VUmc), Amsterdam.
 

August 27, 2008
Rehabilitation programme offers new hope to stroke victims

A new hospital rehabilitation programme has been developed, which "tricks" stroke victims into getting better.

The programme uses a specially-adapted treadmill with virtual reality screens that use moving images to trick the patient's brain into thinking they are walking more slowly than they are, which in turn encourages them to walk faster and further.